Paeoniflorin alleviates ischemia/reperfusion induced acute kidney injury by inhibiting Slc7a11-mediated ferroptosis
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.109754 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Lijuan Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, PR China. Hauptthemen laut MEDLINE: Acute Kidney Injury, Ferroptosis, Reperfusion Injury. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Anhui Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
The pathophysiological mechanism of acute kidney injury (AKI) is complicated, and effective drugs are still lacking. Ferroptosis is a newly discovered regulatory cell death mode characterized by the lethal accumulation of iron and reactive oxygen species-(ROS-)-dependent lipid hydroperoxides. In recent years, ferroptosis has been confirmed to be involved in the progression of AKI. Paeoniflorin (PF) is a traditional Chinese medicine that has protective effects on a variety of kidney diseases including AKI. However, the mechanism by which PF attenuates AKI is unclear. We detected that PF attenuated serum biochemical markers, histological damage, ferroptosis and inflammation in a dose-dependent manner in a mouse AKI model with bilateral renal artery ischemia-reperfusion (IR). Hypoxia-reoxygenation (HR)-induced ferroptosis and inflammation was also inhibited by PF in human renal tubular epithelial cells (HK2). RNA sequence analysis revealed that PF inhibited ferroptosis in HK2 cells by upregulating Slc7a11 in the glutathione pathway after HR treatment. PF failed to further protect cells with specific knockdown of Slc7a11 from ferroptosis under HR conditions. Consequently, these data indicated that PF prevention of ferroptosis in AKI requires dependence on Slc7a11. This study provided a scientific basis for the clinical search for drugs to prevent IR induced AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, PR China.
- Department of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, PR China. Electronic address: aysnzenghx1994@163.com.
- Department of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, PR China; Center for Scientific Research of Anhui Medical University, Hefei, Anhui 230022, PR China. Electronic…
Förderung
- Anhui Medical University
- National Natural Science Foundation of China
Zitieren
APA
Ma, L., Liu, X., Zhang, M., Zhou, L., Jiang, L., Gao, L., Wang, X., Huang, Y., Zeng, H., & Wu, Y. (2023). Paeoniflorin alleviates ischemia/reperfusion induced acute kidney injury by inhibiting Slc7a11-mediated ferroptosis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.109754
Vancouver
Ma L, Liu X, Zhang M, Zhou L, Jiang L, Gao L, et al. Paeoniflorin alleviates ischemia/reperfusion induced acute kidney injury by inhibiting Slc7a11-mediated ferroptosis. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.109754
BibTeX
@article{Ma2023,
author = {Ma, Lijuan and Liu, Xueqi and Zhang, Mengya and Zhou, Lang and Jiang, Ling and Gao, Li and Wang, Xian and Huang, Yuebo and Zeng, Hanxu and Wu, Yonggui},
title = {Paeoniflorin alleviates ischemia/reperfusion induced acute kidney injury by inhibiting Slc7a11-mediated ferroptosis},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.109754}
}
EUVIMED